The alternative protein did not fail. But he also didn't deliver what he promised. The expectation cycle that put Beyond Meat on the stock market in 2019 and made analysts project a food transition in ten years met the most predictable resistance possible: consumers buy the new product, try it, and don't come back. The mistake was not betting on the category. It was confusing curiosity with behavior change, and getting into scale before solving the product. What this implies for food companies in 2026 depends on which of the three categories you're looking at — and each has a different trajectory.
Plant-based: the real problem is not the meat
The narrative that dominated the plant-based sector for years was that the obstacle was taste and texture. Solve the product, and the consumer migrates. But repurchase rates for Beyond Burger and Impossible Burger show the problem runs deeper than palatability. The product resolved taste and texture reasonably well, and repurchase continued to be weak. What has not been resolved is the perceived value of repetition: the consumer pays more, the culinary result is similar but not identical, and without a clear health benefit that is communicable in a simple way, the motivation to buy again drops.
What worked in the plant-based category was not direct meat replacement. It was applied where the vegetable product is naturally superior or neutral: oat milk in coffee, tofu in Asian preparations, vegetable proteins in bars and supplements. Here the comparison with the animal version is not the frame — the product exists on its own merit. Food companies that want real plant-based exposure should be thinking about categories where plant-based is the desired attribute, not a compromise.
Cultured meat: the numbers that no one is sharing
The cost of producing cultured meat has fallen dramatically since 2013, when the first cell-fed burger cost $330,000. But the current production cost — between $10 and $25 per kilogram depending on the product and company — is still between three and ten times the wholesale price of conventional beef, and that's before considering the distribution and retail margin. The question of when cultured meat reaches cost parity with animal meat is now the category's most relevant question, and projections vary too much to be reliable.
The remaining technical bottlenecks are three: the cost of the cell culture medium, which represents the largest fraction of the production cost; the scale of bioreactors, which has not yet been demonstrated commercially above a few thousand liters; and regulation, which has advanced in the United States and Singapore but remains undefined in most relevant markets. Brazil's Ministry of Agriculture does not yet have a clear framework for approving cultured meat, which means the domestic market will not absorb the product at scale in the next three to five years regardless of any technical advances.
For Brazilian food companies, the strategic position in relation to cultured meat is to monitor, not invest. The cost parity horizon is still too uncertain to justify capital in its own infrastructure. But not building internal knowledge about the technology is also a mistake — when the product reaches the market, the competitive advantage will lie with those who understand the production process, not those who read the press release.
Precision Brewing: The Quiet Category That's Working
Precision fermentation is the category that hasn't made the consumer news, but is delivering real commercial results. The model is different from the other two: instead of creating a product for the end consumer, it produces specific ingredients with properties identical to the animal versions — milk protein without the cow, albumin without the egg, collagen without the cowhide. The customer is the industry, not the consumer.
Perfect Day already sells fermented milk protein to ice cream and supplement brands in the United States. Clara Foods produces functional egg whites without the chicken. These products have GRAS approval in the United States and are being analyzed through the Novel Foods process in Europe. In Brazil, ANVISA regulation does not yet have a clearly defined path for ingredients produced by precision fermentation, which is both a barrier to import and a window for local regulatory development.
The business case for precision brewing doesn't depend on convincing consumers to give up anything. The ingredient enters the formulation without changing the communication of the final product — the ice cream is still ice cream, only the protein came from a bioreactor instead of a cow. This model has much more traction with processed food companies than any direct animal protein replacement.
The decision map by category
Food companies with exposure to animal protein have four options for each category: actively invest, establish an exploration partnership, monitor without committing capital, or consciously ignore it because it is not relevant to the portfolio. Confusing these options is the industry's most expensive mistake. Ignoring precision fermentation because you are monitoring cultured meat is an implicit strategy, not an absence of strategy.
The decision criteria should be: what is the time horizon over which this technology could affect the cost or competitive position of your core business? For companies with exposure to dairy and eggs, precision fermentation is a short- to medium-term pressure—five to ten years—and deserves active attention. For raw beef protein, cultured meat is a long-term pressure — more than ten years in Brazil — and justifies monitoring without capital commitment. For plant-based, the right question is not whether the technology will arrive, but in which specific categories of your portfolio it is relevant.
The temptation to have a position in all categories at the same time, usually via a portfolio of small investments in several startups, produces exposure without knowledge. A minority stake in a cultured meat company does not create the ability to understand bioreactors. What builds competitive advantage is depth in at least one of these technologies, not superficial coverage of them all.
Also read
- Lean product development in companies: how to plan without killing speed along the way
- Quantum Readiness for Leaders: What to Do (and Not to Do) Now
- Regulation as a stage: how technology companies navigate complex regulatory environments
- Biomanufacturing: when biology becomes a production line
- How to Position a Software House and Stop Competing on Price
- The Slow Attention Economy: why depth counts again